â– LECTURE OVERVIEW: McArdle Disease (Glycogen Storage Disease Type V) is a benign, muscle-specific metabolic disorder characterized by an inability to mobilize skeletal muscle energy stores during exercise.
â– MYOCELLULAR PATHWAYS:
1. Specific Myophosphorylase Mutation: Caused by autosomal recessive mutations in the PYGM gene, which encodes the skeletal muscle-specific isoform of Glycogen Phosphorylase (myophosphorylase).
2. Isolation of Defect: The hepatic isoform (PYGL) and cardiac isoform are intact; thus, blood glucose regulation and cardiac performance are completely unimpaired.
3. Muscle Glycogen Splitting Deficit: Skeletal muscle cells cannot break glycogen into glucose-1-phosphate, leaving working muscles depleted of immediate anaerobic fuel during the onset of physical exertion.
4. Kinetic Blockade: Lactic acid production is severely impaired, as the glycolytic substrates are unavailable to undergo fermentation.
â– CLINICAL COMPLICATIONS:
Delayed or incomplete treatment triggers cascading systemic strain, involving downstream organ failure, severe metabolic imbalances, or progressive tissue necrosis.
â– EPIDEMIOLOGICAL PROFILE & DENSITY CORRELATIONS:
Global burden patterns reveal notable associations with lifestyle habits, regional environmental factors, and inherited traits.
[HY-BOARD-1347]
🌟 Dynamic Clinical Key:
Classic presentation includes severe muscle cramping, fatigue, and pain during the first few minutes of strenuous exercise, which improves upon resting for a few minutes (the 'second wind' phenomenon, driven by fatty acid mobilization and increased femoral blood flow). Forearm ischemic exercise reveals flat venous lactate curve but a normal rise in ammonia. Early aggressive resuscitation is key to prevent irreversible multi-system organ dysfunction. Focus screening efforts on high-risk geographic regions to maximize clinical yield.